Parents learn about HPV vaccine through DTC ads

Share this article:
A majority of parents and healthcare providers of young women are aware of human papillomavirus (HPV), and most of them learned of the HPV vaccine through drug advertising, a study from the University of North Carolina found.

Additionally, African-Americans—whom are twice as likely to die from HPV—were less exposed to HPV advertising, and less aware of the disease than whites, according to Noel Brewer, an author on the study.
“It's a mixed bag,” said Brewer. “The public has benefited from advertising—without ads, few would get the vaccine. But we want to make sure [consumers] are getting balanced information.”

Brewer acknowledged that the Centers for Disease Control has provided health information related to HPV and the HPV vaccine, but says pharmaceutical marketing has a greater reach. “It's an issue of scale. Pharma is making $360 each time the vaccine is administered,” said Brewer. “Increasingly, drug advertising will carry the day.”

Of the 83% of parents and healthcare providers who had heard of HPV, 82% were aware of the vaccine. However, 87% of whites surveyed had heard of the vaccine, compared with 68% of African-Americans. The study, published in Cancer Epidemiology Biomarkers & Prevention, surveyed 889 caregivers of adolescent girls ages 10 to 18 years in North Carolina.

Approved by the FDA in June 2006, Merck's Gardasil is the only HPV vaccine currently on the market.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Features

Journal Ad Review: Reality Bites

Journal Ad Review: Reality Bites

Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what ...

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...